HR, If AMRN stays independent it will "diversify" its revenue stream. That would require acquisitions which would be dilutive. BP may end up paying full value (if they acquire AMN) for the CVD indication...but they will make money on various future indications such as COPD, DES, and cancer. At least that is way I see it.
Market Data 
Markets 
AI
